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Background: Right ventricular dysfunction (RVD) in acute pulmonary embolism (APE) can be assessed with helical
computerized tomography (CT) and transthoracic echocardiography (TTE). Signs of RVD and elevated natriuretic
peptides like NT-proBNP and cardiac troponin (TnT) are associated with increased risk of mortality. However, the
prognostic role of both initial diagnostic strategy and the use of NT-proBNP and TnT for screening for long-term
probability of RVD remains unknown. The aim of the study was to determine the role of helical CT and NT-proBNP
in detection of RVD in the acute phase. In addition, the value of NT-proBNP for ruling out RVD at long-term follow-
up was assessed.
Methods: Sixty-three non-high risk APE patients were studied. RVD was assessed at admission in the emergency
department by CT and TTE, and both NT-proBNP and TnT samples were taken. These, excepting CT, were repeated
seven months later.
Results: At admission RVD was detected by CT in 37 (59 %) patients. RVD in CT correlated strongly with RVD in
TTE (p< 0.0001). NT-proBNP was elevated (≥ 350 ng/l) in 32 (86 %) patients with RVD but in only seven (27 %)
patients without RVD (p< 0.0001). All the patients survived until the 7-month follow-up. TTE showed persistent RVD
in 6 of 63 (10 %) patients who all had RVD in CT at admission. All of them had elevated NT-proBNP levels in the
follow-up compared with 5 (9 %) of patients without RVD (p< 0.0001).
Conclusions: TTE does not confer further benefit when helical CT is used for screening for RVD in non-high risk
APE. All the patients who were found to have RVD in TTE at seven months follow-up had had RVD in the acute
phase CT as well. Thus, patients without RVD in diagnostic CT do not seem to require further routine follow-up to
screen for RVD later. On the other hand, persistent RVD and thus need for TTE control can be ruled out by
assessment of NT-proBNP at follow-up. A follow-up protocol based on these findings is suggested.
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Right ventricular dysfunction (RVD) is an independent
and important predictor of early death in patients with
acute pulmonary embolism (APE) [1-4].
Transthoracic echocardiography (TTE) is regarded as
the most reliable method for assessment of RVD. On the
other hand, low levels of brain natriuretic peptide (BNP)
and N-terminal (NT)-proBNP seem reliable for ruling
out RVD [5-10]. Combination of NT-proBNP with TTE
may permit the identification of both non-high and
high-risk patients with APE [10,11]. Currently, helical
CT is the first-line imaging investigation in patients with
suspected APE [12-15]. Helical CT can also be used to
assess RVD. RVD detected by helical CT correlates with
RVD determined by TTE [16]. RV enlargement on CT has
been reported to predict early clinical outcome [17-20].
The data on the natural history of APE with respect to
persistent RVD after hospital discharge is sparse. In
study of Ribeiro et al in 1999 [21] an echocardiography
performed six weeks after APE could identify patients
with persistent RVD. According to our knowledge there
are only a few prospective follow-up studies concerning
non-high risk APE and in most of these studies RVD has
been detected in the acute phase by TTE [22,23]. In a
few follow-up studies diagnosis of initial RVD has been
done by CT. Van der Meer et al. in 2006 [17] reported a
three months follow-study in which RVD was assessed
by CT at baseline. In that study RVD was found to pre-
dict mortality after initial hospitalization in patients with
both massive and submassive APE. Golpe et al [24]
followed APE patients for six months where the diagno-
sis was initially confirmed by CT. As far as we are aware
there are no follow-up recommendations for patients
with APE and RVD.
The aim of this study was to determine the role of
helical CT and NT-proBNP in detection of RVD in the
acute phase. In addition, the value of NT-proBNP for
ruling out RVD at long-term follow-up was assessed.
Methods
This study was conducted in Helsinki University Central
Hospital, Helsinki, Finland between February 2003 and
August 2004. Sixty-three consecutive patients of all diag-
nosed 261 patients at Emergency department (ED) were
included in the study with a similar clinical management
protocol. Subjects with high-risk APE (haemodynamically
unstable patients), chronic pulmonary disease with regular
ongoing medication, history of previous APE, ongoing
anticoagulation therapy, end-stage cancer (estimated life
expectancy less than seven months) were excluded from
the study. There were several patients who were referred
to the ED only for diagnostic investigations from the
surrounding local hospitals and returned there for further
treatment. There was also another PE study ongoing inhospital at the time of the present study. Those patients
were excluded from the present study as well.
At admission RVD was assessed by CT and the patients
were grouped as RVD positive and RVD negative. TTE
was performed within 12 hours. ECG and samples for NT-
proBNP and TnT were taken on admission. TTE, cardiac
biomarkers and clinical evaluation were repeated seven
months later.
A detailed medical history was recorded on admission
including information on risk factors for thrombo-
embolic events (such as age, gender, immobilization the
preceding three months, hormone replacement or hor-
monal contraception therapy, family history of venous
thromboembolism, active cancer, varicose veins, smoking
and overweight).
A twelve-lead ECG was recorded on admission. Estab-
lished criteria for RVD were used: T-wave inversion in
leads V1 to V3, incomplete or complete right bundle
branch block, S1Q3T3 pattern, and the presence of P
pulmonale [25,26]. If any of these findings were present
the patient was categorized as having RVD from the
ECG.
An arterial blood gas analysis was performed on
admission. Hypoxemia was defined as arterial pO2 below
11 kPa and hypocapnia as arterial pCO2 below 4.5 kPa.
Blood pressure was measured and all patients underwent
ultrasound examination of the lower limb veins.
Blood samples for plasma NT-proBNP, cardiac tropo-
nin T (cTnT) and D-dimer (fibrin degradation product)
were collected on admission and analyzed using com-
mercially kits: NT-proBNP (Roche Diagnostics Elecsys),
cTnT (Roche Diagnostics Elecsys) and D-dimer (Roche
Diagnostics Tina-Quant). An NT-proBNP value ≥ 350
ng/l was regarded as elevated. The cut-off level 350 ng/l
was chosen because according to our local laboratory
reference values≥ 350 ng/ml are abnormal irrespective
of age and sex. The assay specific cut-offs for cTNT
(>0.03 ug/l) and for D-dimer (≥0.5 mg/l) were used. All
the subjects were tested for thrombophilia in the routine
tests of the local laboratory (activated protein C resist-
ance, factor V Leiden mutation assay, prothrombin
20210 mutation assay, lupus anticoagulant testing, antic-
ardiolipin IgG antibodies, beta2-glycoprotein 1 (beta2-
GP1) antibodies, antithrombin activity, factor VIII activ-
ity, protein C activity and protein S activity).
The helical CT scan was performed as a part of the
initial diagnostic work-up. Thirty-six CT examinations
were performed with an 8-slice-scanner (GE Light Speed
Ultra), 22 with a four-slice-scanner (22 with Philips
Mx8000, one with GE High Speed) and five with a single
slice scanner (GE High Speed LX/i). The volume of con-
trast material varied from 90 to 120 ml and was injected
using bolus tracking with a power injector 4 ml/s. The
collimation was 1 to 1.25 mm but 3 mm collimation with
Table 1 Characteristics and risk factors of 63 patients
Characteristics and risk factors of 63 patients
Variable Patients, n (%)
Age >75 years 10 (16)
Gender
Male 30(48)
Female 33 (52)
Body mass index >25 kg/m2 50 (79)
Immobilization 28 (44)
(prolonged immobility, hospitalization, surgery within 3 months)
HRT * 7 (11)
Hormonal contraception 6(10)
History of DVT** 7 (11)
Family history of VTE*** 5 (8)
Thrombophilia**** 9 (14)
Active cancer 3 (5)
Varicose veins 27 (43)
Diabetes mellitus 5 (8)
Smoking
Smoker 11 (17)
Ex-smoker 19 (30)
Non-smoker 33 (52)
* HRT =Hormone replacement therapy.
**DVT =Deep venous thrombosis.
*** VTE = Thromboembolic disease.
**** Known previously or detected in clinical laboratory tests.
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CT scans were evaluated by two experienced radiologists
who were blinded to the clinical findings. The left and
right ventricular (LV, RV) diameters were measured on
the axial image where the ventricles were their widest.
The septum was evaluated as normal, straightened or
bowed toward the left ventricle.
The criteria for RVD were RV/LV ratio over 1.0 and/or
deviation (straightening or bowing) of the interventricular
septum [16,27].
TTE was performed within 12 hours after the diagnosis
of APE using the Vivid Digital Ultrasonography System
(GE Vivid 5 or Vivid 7, Horten, Norway). Recordings on
M-mode, two-dimensional color-flow, and Doppler were
stored on a magneto-optic disc. Most of the patients were
examined both in a left lateral and in a flat supine position.
Parasternal and apical views were preferred. All the studies
were performed by one of three experienced cardiologists.
TTE was repeated seven months later by the same cardi-
ologist as on admission. The analyses and measurements
were carried out from stored data of the recordings and
the investigators were blinded to all the clinical data.
Presence of RVD was assessed using the following estab-
lished criteria: 1) the ratio of RV and left ventricular end-
diastolic diameter (RV/LV) above 1.0, 2) the presence of
paradoxical septal wall motion, and 3) mean TR peak
velocity greater than 2.8 m/s. At least one of these criteria
had to be positive.
Statistical analyses were performed with SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL, USA). The subjects
were categorized according to CT findings into two
groups: RVD positive and RVD negative. Data are pre-
sented as frequencies or percentages for categorical vari-
ables and as mean (SD) for continuous variables, unless
otherwise noted. Normality of continuous variables was
checked by the Kolmogorov-Smirnov test. Between-
group differences were assessed by the Mann–Whitney
U-test. Categorical data were compared by the chi-
square test or Fischer´s exact test. P-values <0.05 were
considered statistically significant.
This study was approved by the Ethics Committee of
the Helsinki University Central Hospital, and written
informed consent was obtained from all participants.
Results
The clinical characteristics of the patients (30 males and
33 females) with a mean age of 55 years, range 18 to
86 years, and risk factors for venous thromboembolism
are represented in Table 1. Risk factors for venous
thromboembolism were similar in RVD negative and
positive groups (data not shown). No patient had an
acute coronary syndrome according to established clin-
ical criteria. All the patients had normal left ventricular
systolic function in TTE.All the patients were initially treated in hospital and
stayed in an observation unit if clinically necessary.
Three patients in the RVD positive group received
thrombolysis as a 2-hour alteplase infusion. All the
patients received subcutaneous low molecular weight
heparin in a weight-adjusted dose followed by warfarin
for at least six months. There were no bleeding compli-
cations. All the patients survived until the seven months
follow-up visit. The mean initial systolic blood pressure
was 140 (SD 21) and diastolic 83 (SD 13) mmHg.
Right ventricular overload was detected with CT in 37
patients (59 %). (Figure 1).
Both increased RV/LV ratio and septum deviation were
observed in 27 (73 %) patients whereas only septum devi-
ation was observed in 7 (19 %) patients and increased
RV/LD ratio in 3 (8 %).
Twenty-eight patients (76 %) in the RVD positive group
also had signs of RVD in TTE. Nine of the RVD positive
patients (24 %) showed no echocardiographic alterations of
RV morphology or function. Overall findings of RVD in
CT correlated strongly with those in echocardiography (p
< 0.0001). Findings suggesting RVD were found with TTE
in three of the initially RVD negative patients. The only
sign of RVD in these patients was as a slightly increased
mean tricuspid regurgitation peak velocity of 2.9-3.1 m/s.
RVD Positive 
(n= 37)
RVD Positive 
(n=28)
RVD Negative 
(n=9)
RVD Positive 
(n=6)
RVD Negative
(n= 26)
RVD Positive 
(n=3)
RVD Positive 
(n=0)
RVD Negative 
(n=31)
RVD Negative 
(n=23)
Evaluation of right ventricular overload with CT 
RVD Negative
(n=26)
Investigated for 
APE
(n=261)
Recruited  to the 
study
(n=63)
Initial
ECHO
Initial
CT
ECHO
7 mo.
)3=n()22=n(
Figure 1 Evaluation of right ventricular overload with CT. Computerized tomography (CT) Right ventricular dysfunction (RVD)
Echocardiography (ECHO).
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(86 %) had elevated NT-proBNP level in contrast to only
7 patients (27 %) of patients without RVD (p< 0.0001).
TnT was above the reference value in 11 patients (17 %),
nine of them (82 %) in RVD positive and two (18 %) in
RVD negative group( p< 0.082 ).
Signs of RV overload in the ECG on admission were
detected in 32 (51 %) patients. In the RVD positive
group 24 patients (87 %) had signs of RV overload in the
ECG whereas eight patients (13 %) had such findings in
the RVD negative group (p< 0.0001).
Arterial blood gas analysis was available in 60 patients.
Arterial hypoxemia was detected in 56 (93 %) and hypo-
capnia in 27 (45 %). RVD positive patients (n = 37) had
hypoxia and hypocapnia (n = 36) significantly more often
than the RVD negative group patient (p< 0.0001). The
elevated D-dimer level was detected in all patients. The
mean levels of D-dimer did not differ between the study
groups; 10 (SD 7) mg/l in the RVD and 7 (SD 7) mg/l in
the RVD negative group (p< 0.102). The prevalence of
DVT was similar in both groups ; DVT was diagnosed
in 32 patients (51 %), 18 (56 %) in the RVD positive and
14 (44 %) in the RVD negative group (p> 0.05).
At the seven-month follow-up persistent RVD was
detected by echocardiography in 6 (10 %) of all the
patients. CT detected every patient who had persistent
RVD at 7 months, a sensitivity of 100 %, 95 % CI (54 %,
100 %). All these 6 patients had elevated NT-proBNP
levels in the follow-up compared with 5(9%) patientswithout RVD (p< 0.0001). All the patients who were
found to have persistent RVD, had RVD in both CT and
TTE at admission. On the other hand the lack of RVD
in CT at admission predicted normal RV function at
follow-up in 26 out of 57 patients, with specificity of
46 %,(95 % CI 32-, 59 %).
Discussion
This prospective follow-up study of non-high risk APE
patients shows that helical CT is a practical and valuable
method for detection of RVD in clinical practice. Fur-
thermore, normal RV findings in CT as well as NT-
proBNP level ≤ 350 ng/l excluded RVD both in the acute
phase and at seven months follow-up.
In our study RVD was detected with CT in 59 % of
patients with non-high risk APE. In earlier CT imaging
studies which have included both massive and non-
massive PE, RVD has been reported in 58 % to 64 % of
patients [16,17,28]. Our results also are in agreement
with earlier studies in which RV dysfunction has been
detected with TTE in approximately 50 % of patients
[1,3,28-30]
There were 9 patients in whom RVD was observed in
CT but not in TTE. This could be owing to the difference
in timing of the investigations. CT was performed as a
routine diagnostic imaging study of APE in the ED
whereas TTE was recorded within 12 hours. It is possible
that some minor RVD changes had already normalized
within 12 hours after initializing the treatment for APE.
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had only borderline increase in the maximal velocity of
TR, a finding which may be considered unspecific.
Our study demonstrates that NT-proBNP is valuable
in ruling out the probability of RVD. Previous studies
have indicated that NT-proBNP may be useful in the
identification of non-high and high-risk patients and low
plasma NT-proBNP levels predicts an uncomplicated
clinical hospital course in APE patients [6,8]. In the
present study, however, the hospital course of all the
patients was uncomplicated regardless of the NT-
proBNP level, and all study patients survived throughout
the follow-up time. Thus the role of NT-proBNP for
predicting mortality risk could not be evaluated in the
present study. However, level of NT-proBNP under ≤ 350
ng/l at admission excluded development of persistent
RVD during follow-up. A normal NT-proBNP at follow-
up also was a valuable tool for screening out RVD dur-
ing follow-up; none of the patients with a normal NT-
proBNP were found to have persistent RVD.
The International Collaborative Study on NT-proBNP
has established cut-off values for NT-proBNP in acute
heart failure [31-34]. According to this study an NT-
proBNP value below 300 ng/ml could be used to rule out
heart failure. On the other hand studies in APE have used
500 ng/l as a cut-off for RVD [35] and 1000 ng/l[10] which
also predict unfavorable outcome in PE. In our study the
upper limit of the local normal range, i.e. 350 ng/l, was
chosen as the cut-off level. One can assume that a lower
cut-off might increase sensitivity but decrease specificity
of the marker.
TnT -values did not differ significantly between the
RVD positive and negative groups which was expected
result since high-risk PE patients were excluded from
the study. Acute coronary syndrome was excluded from
all the patients using established clinical criteria.
The ECG and arterial blood gas analysis proved to be
valuable tools when assessing the probability of RVD in
acute PE. Patients with RVD showed significantly more
often both ECG findings and abnormal gas analysis
compared to those without it.
One may consider performing CT and TTE not exactly
simultaneously as a limitation to the study. However, this
most often is the case in clinical practice and also in pre-
vious studies (24). Moreover, the primary purpose of this
study was not to compare CT and TTE with each other.
At seven-month follow-up only TTE was done in order
to avoid radiation. None of the patients died during the
follow-up. On the other hand we did not aim to analyze
prognostic effects on mortality since the limited number
of patients does not allow further conclusions on sur-
vival. The present study found persistent RVD in 10 % of
all study patients at seven-month follow-up. Earlier fol-
low-up studies have detected RVD in 6 to 20 % ofpatients [24,36]. In our study every patient with RVD at
follow-up also had RVD in the initial CT and TTE. On the
other hand none of the patients with a normal NT-
proBNP at follow-up had persistent RVD.
In study by Pengo et al [37] the investigators found
symptomatic chronic thromboembolic pulmonary hyper-
tension (CTPH) in 4 percent of patients after two years of
first episode of symptomatic pulmonary embolism. Thus,
the incidence of CTPH is not rare. According to our
knowledge there are not available systematic follow-up
protocols for APE patients. However, in clinical practice
there is a real need for them.
Conclusions
In conclusion, the present study shows that CT is a
practical and valuable imaging method for detection of
RVD in non-high risk APE patients. In this study all the
patients who were found to have RVD at the seven
months follow-up also had RVD in the acute phase CT
and TTE. Furthermore, NT-proBNP level ≤ 350 ng/l
excluded RVD at the seven months follow-up.
According to these results we suggest a follow-up
protocol, in which patients with RVD on admission CT
are rescreened during the follow-up by measuring NT-
proBNP levels. If the levels are elevated an echocardiog-
raphy is performed. Timing of the follow-up visit and
NT-proBNP rescreening to the point of the planned dis-
continuation of anticoagulation treatment might be ap-
propriate. Alternatively, if anticoagulation therapy is to
be permanent then biomarker screening might be done
from six to twelve months after APE. This suggested fol-
low-up protocol needs to be validated in a larger patient
population.
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